MX2017010544A - Metodos y composiciones para tratar la enfermedad del ojo seco y otros trastornos del ojo. - Google Patents
Metodos y composiciones para tratar la enfermedad del ojo seco y otros trastornos del ojo.Info
- Publication number
- MX2017010544A MX2017010544A MX2017010544A MX2017010544A MX2017010544A MX 2017010544 A MX2017010544 A MX 2017010544A MX 2017010544 A MX2017010544 A MX 2017010544A MX 2017010544 A MX2017010544 A MX 2017010544A MX 2017010544 A MX2017010544 A MX 2017010544A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- eye
- compositions
- eye disorders
- treating dry
- Prior art date
Links
- 208000030533 eye disease Diseases 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 4
- 208000003556 Dry Eye Syndromes Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 239000000384 adrenergic alpha-2 receptor agonist Substances 0.000 abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 2
- 206010013774 Dry eye Diseases 0.000 abstract 1
- 206010065062 Meibomian gland dysfunction Diseases 0.000 abstract 1
- 230000000699 topical effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562119857P | 2015-02-24 | 2015-02-24 | |
| PCT/US2016/019207 WO2016138049A1 (en) | 2015-02-24 | 2016-02-23 | Methods and compositions for treating dry eye disease and other eye disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017010544A true MX2017010544A (es) | 2018-06-18 |
Family
ID=56692824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017010544A MX2017010544A (es) | 2015-02-24 | 2016-02-23 | Metodos y composiciones para tratar la enfermedad del ojo seco y otros trastornos del ojo. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9597328B2 (enExample) |
| EP (1) | EP3261620B1 (enExample) |
| JP (1) | JP2018506570A (enExample) |
| KR (1) | KR20170132725A (enExample) |
| CN (1) | CN107427459A (enExample) |
| AU (1) | AU2016222902A1 (enExample) |
| BR (1) | BR112017017448A2 (enExample) |
| CA (1) | CA2976120A1 (enExample) |
| ES (1) | ES2936394T3 (enExample) |
| MX (1) | MX2017010544A (enExample) |
| RU (1) | RU2691412C2 (enExample) |
| WO (1) | WO2016138049A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7981145B2 (en) | 2005-07-18 | 2011-07-19 | Tearscience Inc. | Treatment of meibomian glands |
| US20070060988A1 (en) | 2005-07-18 | 2007-03-15 | Grenon Stephen M | Melting meibomian gland obstructions |
| US20070016256A1 (en) | 2005-07-18 | 2007-01-18 | Korb Donald R | Method and apparatus for treating gland dysfunction |
| US20080114423A1 (en) | 2006-05-15 | 2008-05-15 | Grenon Stephen M | Apparatus for inner eyelid treatment of meibomian gland dysfunction |
| WO2016022066A1 (en) | 2014-08-04 | 2016-02-11 | Jerry Tan Eye Surgery Pte Ltd | Pharmaceutical compositions for demodex related blepharitis and eyelid crusting |
| US11478437B2 (en) * | 2016-07-05 | 2022-10-25 | Jenivision Inc. | Formulations for hair growth |
| WO2018212846A1 (en) * | 2017-05-19 | 2018-11-22 | Ocugen, Inc. | Ophthalmic compositions and methods of use |
| CA3080166A1 (en) * | 2017-11-21 | 2019-05-31 | Axerovision, Inc. | Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface |
| US11759472B2 (en) * | 2017-11-21 | 2023-09-19 | Cs Pharmaceuticals Limited | Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface |
| KR20250065422A (ko) | 2017-12-15 | 2025-05-12 | 타르서스 파마수티칼스, 아이엔씨. | 안검염을 치료하기 위한 이속사졸린 구충제 제제 및 방법 |
| JP6653037B2 (ja) * | 2018-03-30 | 2020-02-26 | 千寿製薬株式会社 | 水性液剤 |
| JP6621955B2 (ja) * | 2018-03-30 | 2019-12-18 | 千寿製薬株式会社 | 水性液剤 |
| US11077053B2 (en) | 2018-08-21 | 2021-08-03 | Allergan, Inc. | Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia |
| CA3115664A1 (en) * | 2018-08-29 | 2020-03-05 | Ocugen, Inc. | Ophthalmic compositions and methods of use |
| KR20220084381A (ko) * | 2019-12-10 | 2022-06-21 | 알콘 인코포레이티드 | 생분해성 중합체를 갖는 용해성 중합체 눈 삽입물 |
| US20230302032A1 (en) * | 2020-08-04 | 2023-09-28 | Harrow Ip Llc | Antibacterial compositions and methods for fabricating thereof |
| CA3199736A1 (en) | 2020-11-23 | 2022-05-27 | Sight Sciences, Inc. | Formulations and methods for treating conditions of the eye |
| CN116710087A (zh) * | 2020-11-23 | 2023-09-05 | 美国商业眼科医疗器械公司 | 用于治疗眼部病症的制剂和方法 |
| CN115645356A (zh) * | 2022-11-21 | 2023-01-31 | 山东诺明康药物研究院有限公司 | 一种酒石酸溴莫尼定原位凝胶及其制备方法和应用 |
| WO2025174723A1 (en) * | 2024-02-12 | 2025-08-21 | Selagine Inc. | Ophthalmic composition comprising cethromycin |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK3412U (sk) * | 2002-07-01 | 2003-01-09 | Unimed Pharma Spol Sro | Očná inštalácia so zlepšenou stabilitou účinnej látky na báze brimomidínu |
| US20040088199A1 (en) * | 2002-10-31 | 2004-05-06 | Childress Allen B. | Method of forming a business rule |
| US20050196370A1 (en) * | 2003-03-18 | 2005-09-08 | Zhi-Jian Yu | Stable ophthalmic oil-in-water emulsions with sodium hyaluronate for alleviating dry eye |
| WO2006004577A2 (en) * | 2004-03-12 | 2006-01-12 | Melbj Holdings, Llc | Lubricant for the ocular surface |
| MX2009000885A (es) * | 2006-07-25 | 2009-02-05 | Osmotica Corp | Soluciones oftalmicas. |
| US9125807B2 (en) * | 2007-07-09 | 2015-09-08 | Incept Llc | Adhesive hydrogels for ophthalmic drug delivery |
| CN101352441A (zh) * | 2007-07-27 | 2009-01-28 | 肖正连 | 一种酒石酸溴莫尼定眼用即型凝胶 |
| US20120003296A1 (en) * | 2010-07-01 | 2012-01-05 | Shantha Totada R | New methods of treating dry eye syndrome |
| CA2808307C (en) | 2010-08-16 | 2022-06-21 | Allergan, Inc. | Method of activating regulatory t cells with alpha-2b adrenergic receptor agonists |
| US20120082625A1 (en) * | 2010-09-28 | 2012-04-05 | Michael Graeber | Combination treatment for rosacea |
| US20120076738A1 (en) * | 2010-09-28 | 2012-03-29 | Michael Graeber | Combination treatment for dermatological conditions |
| US20120093876A1 (en) * | 2010-10-13 | 2012-04-19 | Aciex, Inc. | Ophthalmic Formulations, Methods Of Manufacture And Methods of Normalizing Meibomian Gland Secretions |
| MX346312B (es) * | 2011-04-05 | 2017-03-15 | Optosolve Res & Dev Ltd | Tratamientos oftalmicos. |
| EP2630952A1 (en) * | 2012-02-23 | 2013-08-28 | Novagali Pharma S.A. | Self-preserved oil dispersions comprising boric acid |
-
2016
- 2016-02-23 AU AU2016222902A patent/AU2016222902A1/en not_active Abandoned
- 2016-02-23 RU RU2017129247A patent/RU2691412C2/ru active
- 2016-02-23 BR BR112017017448A patent/BR112017017448A2/pt not_active Application Discontinuation
- 2016-02-23 KR KR1020177023704A patent/KR20170132725A/ko not_active Withdrawn
- 2016-02-23 WO PCT/US2016/019207 patent/WO2016138049A1/en not_active Ceased
- 2016-02-23 ES ES16756227T patent/ES2936394T3/es active Active
- 2016-02-23 JP JP2017545544A patent/JP2018506570A/ja active Pending
- 2016-02-23 US US15/051,654 patent/US9597328B2/en active Active
- 2016-02-23 MX MX2017010544A patent/MX2017010544A/es unknown
- 2016-02-23 CN CN201680011749.3A patent/CN107427459A/zh active Pending
- 2016-02-23 EP EP16756227.1A patent/EP3261620B1/en active Active
- 2016-02-23 CA CA2976120A patent/CA2976120A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3261620A4 (en) | 2018-10-31 |
| JP2018506570A (ja) | 2018-03-08 |
| AU2016222902A1 (en) | 2017-08-31 |
| RU2017129247A (ru) | 2019-03-25 |
| BR112017017448A2 (pt) | 2018-04-03 |
| ES2936394T3 (es) | 2023-03-16 |
| CA2976120A1 (en) | 2016-09-01 |
| US9597328B2 (en) | 2017-03-21 |
| WO2016138049A1 (en) | 2016-09-01 |
| CN107427459A (zh) | 2017-12-01 |
| EP3261620A1 (en) | 2018-01-03 |
| RU2691412C2 (ru) | 2019-06-13 |
| EP3261620B1 (en) | 2022-11-09 |
| KR20170132725A (ko) | 2017-12-04 |
| RU2017129247A3 (enExample) | 2019-03-25 |
| US20160243116A1 (en) | 2016-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017010544A (es) | Metodos y composiciones para tratar la enfermedad del ojo seco y otros trastornos del ojo. | |
| SA518400356B1 (ar) | مثبطات الأرجيناز واستخداماتها العلاجية | |
| MX2021000071A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| EA201890725A1 (ru) | Агонисты фарнезоидного х-рецептора и их применение | |
| WO2015171610A3 (en) | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease | |
| MX2022001310A (es) | Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo. | |
| MX2017016134A (es) | Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad. | |
| PL410665A1 (pl) | Inhibitory arginazy oraz ich zastosowania terapeutyczne | |
| EA201990424A1 (ru) | Спиролактамовые модуляторы nmda-рецептора и их применение | |
| EA201990425A1 (ru) | Спиролактамовые и бис-спиролактамовые модуляторы nmda-рецептора и их применение | |
| EA201990428A1 (ru) | Спиролактамовые модуляторы nmda-рецептора и их применение | |
| MX2019004859A (es) | Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas. | |
| EA201890449A1 (ru) | Фумагиллиновые гетероциклические соединения и способы их получения и применения | |
| SA519410324B1 (ar) | صياغات رش إيبينيفرين | |
| BR112018015367A2 (pt) | carreadores oromucosais de nanofibra para tratamento terapêutico | |
| MX2018008903A (es) | COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA. | |
| EA201691570A1 (ru) | Фармацевтическая композиция, включающая диамино-гетероциклическое карбоксамидное соединение в качестве активного ингредиента | |
| EA201792571A1 (ru) | Терапевтическое применение l-4-хлорокинуренина | |
| CL2018000430A1 (es) | Compuesto de hidroxitriazina y uso médico relacionado. | |
| MX382357B (es) | Métodos y composiciones para tratar infecciones fúngicas cutáneas. | |
| PH12020551179A1 (en) | Methods for treating mitochondrial disorder | |
| ZA201906153B (en) | Pharmaceutical compositions for combination therapy | |
| EP4537846A3 (en) | Anavex2-73 for the treatment of alzheimer s disease | |
| MX2018004777A (es) | Compuestos oxa-diazaspiro que tienen actividad contra el dolor. | |
| AR103636A1 (es) | Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol |